Humacyte, Inc. (HUMA) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 6.93
30Y Low1.8·High21.7
ROE
↓
N/A
—
5yr avg: -68.2%
30Y Low-170%·High-10%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HUMA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Humacyte, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $140M | $598M | $294M | $217M | $290M | $127M | — |
| Enterprise Value | $112M | $570M | $271M | $118M | $123M | $116M | — |
| P/E Ratio → | -0.86 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 138.94 | 229.44 | 84.91 | — |
| P/B Ratio | — | — | 21.68 | 1.86 | 2.37 | 1.79 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HUMA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 75.23 | 97.75 | 77.49 | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
HUMA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | -427.5% | -4756.8% | -3527.0% | -1122.0% |
| Operating Margin | — | — | — | -5404.3% | -6429.8% | -4332.7% | -1385.0% |
| Net Profit Margin | — | — | — | -764.5% | -2096.4% | -4461.7% | -1380.7% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | -169.8% | -10.0% | -27.5% | -65.6% | -64.6% |
| ROA | -111.8% | -111.8% | -66.6% | -4.9% | -13.5% | -48.3% | -50.6% |
| ROIC | — | — | -1930.7% | — | -788.2% | -76.4% | — |
| ROCE | -100.5% | -100.5% | -67.9% | -36.8% | -43.8% | -51.0% | -54.3% |
HUMA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $45M exceeds total debt of $17M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 4.24 | 0.43 | 0.42 | 0.41 | 0.22 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -1.70 | -0.85 | -1.36 | -0.16 | -0.49 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -12.33 | -12.33 | -15.16 | -13.64 | -18.68 | -29.34 | -37.29 |
Net cash position: cash ($45M) exceeds total debt ($17M)
HUMA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Humacyte, Inc.'s current ratio of 2.40x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.88x to 2.40x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.40 | 2.40 | 4.52 | 7.88 | 20.75 | 3.69 | 8.76 |
| Quick Ratio | 2.40 | 2.40 | 4.52 | 7.88 | 20.75 | 3.69 | 8.76 |
| Cash Ratio | 2.25 | 2.25 | 4.36 | 7.76 | 20.41 | 3.55 | 8.64 |
| Asset Turnover | — | — | — | 0.01 | 0.00 | 0.01 | 0.04 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 7.23 | 50.86 | 27.66 | 35.46 |
HUMA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Humacyte, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $118M | $103M | $103M | $40M | $12M | $20M |
Peer Comparison
Compare HUMA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HUMAYou | $140M | -0.9 | — | — | — | — | — | — | — |
 TELA | $44M | -0.8 | — | — | 67.1% | -49.2% | -159.9% | -151.6% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 ANGO | $469M | -13.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 AORT | $2B | 168.5 | 39.5 | — | 61.3% | 6.1% | 2.7% | 3.2% | 5.9 |
 ELMD | $222M | 31.2 | 19.1 | 20.1 | 78.1% | 15.1% | 17.2% | 25.6% | 0.0 |
 LMAT | $2B | 42.8 | 33.4 | 33.0 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 BDX | $56B | 26.3 | 14.7 | 20.8 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See HUMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HUMA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HUMA vs TELA
Side-by-side business, growth, and profitability comparison vs TELA Bio, Inc..
Start ComparisonHUMA — Frequently Asked Questions
Quick answers to the most common questions about buying HUMA stock.
What is Humacyte, Inc.'s P/E ratio?
Humacyte, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
Is HUMA stock overvalued?
Based on historical data, Humacyte, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.